http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png00Kelly Southernhttp://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.pngKelly Southern2023-01-03 14:00:192023-01-03 13:27:26Mission Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png00Kelly Southernhttp://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.pngKelly Southern2022-11-15 09:00:482022-11-14 15:24:42New Data from Harvard Medical School Highlights USP30 Reduction as a Potential Strategy for Treatment of Parkinson’s Disease
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png00Kelly Southernhttp://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.pngKelly Southern2022-10-11 14:44:262022-10-12 09:00:58Mission Therapeutics to attend the Michael J. Fox Foundation’s 14th Annual Parkinson’s Disease Therapeutics Conference
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png00Kelly Southernhttp://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.pngKelly Southern2022-10-11 14:42:102022-10-11 14:51:47Mission Therapeutics to participate in the 9th Annual Solebury Strategic Communications Private Company Showcase
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png00moonbase alphahttp://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.pngmoonbase alpha2022-03-31 11:12:282022-03-31 11:12:28Mission Therapeutics authorised to initiate first clinical trial for lead DUB program, MTX652, in kidney disease
